open access

Vol 10, Supp. C (2019)
Case report
Get Citation

Long-term response to treatment with brentuximab vedotin in a patient with relapse of Hodgkin lymphoma after auto-HSCT

Edyta Subocz1, Janusz Hałka
DOI: 10.5603/Hem.2019.0023
Affiliations
  1. Klinika Chorób Wewnętrznych i Hematologii, Wojskowy Instytut Medyczny, ul. Szaserów 128, 04–141 Warszawa, Poland

open access

Vol 10, Supp. C (2019)
CASE REPORTS

Abstract

The standard of care for patients with refractory or relapsed Hodgkin lymphoma is salvage chemotherapy followed by autologous hematopoietic stem cell transplantation. This method is not always effective, however. For patient who do not respond or those who relapse again treatment opportunities are limited. Before of the brentuximab vedotin ”era” the prognosis of such patients was poor, with a 5-year overall survival not exceeding 30%. Allogeneic stem cell transplantation (allo-HSCT) may be curative, but its success is highly dependent on prior good disease control. Brentuximab vedotin can be effective bridging treatment before allo-HSCT because 34% of patients can achive complete remission. In addition, in some patients, used as monotherapy without additional consolidation treatment allows for long-term responses.

Abstract

The standard of care for patients with refractory or relapsed Hodgkin lymphoma is salvage chemotherapy followed by autologous hematopoietic stem cell transplantation. This method is not always effective, however. For patient who do not respond or those who relapse again treatment opportunities are limited. Before of the brentuximab vedotin ”era” the prognosis of such patients was poor, with a 5-year overall survival not exceeding 30%. Allogeneic stem cell transplantation (allo-HSCT) may be curative, but its success is highly dependent on prior good disease control. Brentuximab vedotin can be effective bridging treatment before allo-HSCT because 34% of patients can achive complete remission. In addition, in some patients, used as monotherapy without additional consolidation treatment allows for long-term responses.

Get Citation

Keywords

chłoniak Hodgkina, brentuksymab vedotin, długotrwała odpowiedź, przeszczepianie krwiotwórczych komórek macierzystych

About this article
Title

Long-term response to treatment with brentuximab vedotin in a patient with relapse of Hodgkin lymphoma after auto-HSCT

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. C (2019)

Article type

Case report

Pages

1-6

DOI

10.5603/Hem.2019.0023

Keywords

chłoniak Hodgkina
brentuksymab vedotin
długotrwała odpowiedź
przeszczepianie krwiotwórczych komórek macierzystych

Authors

Edyta Subocz
Janusz Hałka

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.